The use of genomic tests in patients with breast cancer in Lombardy: a successful healthcare model
Affiliations
- PMID: 32729378
- DOI: 10.1177/0300891620943950
Abstract
Background: The accurate identification of patients with early breast cancer (eBC) suitable for adjuvant chemotherapy is essential in order to avoid overtreatment or undertreatment. For eBC patients with luminal (HR+/HER2-) intermediate risk disease, multigene assays (MGAs) have been convincingly reported to be useful in guiding treatment decisions. The most recently published data and recommendations from main International Guidelines and Heath Technology Assessment reports confirmed the benefit of MGAs in guiding treatment decisions for clinically intermediate risk patients, and led several countries to test reimbursement.
Purpose: This article describes the process followed by the Lombardy region in Italy regarding the reimbursement of MGAs for patients with eBC, based on the results of a prospective clinical trial.
Results: The study shows that the use of Oncotype DX allowed avoiding the use of unnecessary adjuvant chemotherapy in 50% of patients for whom chemotherapy was initially recommended according to traditional clinical practice. On the basis of these data, a group of oncologists in collaboration with a pathologist regional board formally requested authorization for MGA reimbursement in Lombardy. Acknowledging the strategic importance of the proposal, the Lombardy region approved the reimbursement of MGAs for resident patients with luminal eBC at intermediate clinical risk. It can be assumed that about 1500 patients will be tested in Lombardy per year and this should allow the Regional Health Service to save more than 750 chemotherapies/year.
Conclusion: The introduction of MGAs in the clinical evaluation of patients with luminal eBC with intermediate risk is economically sustainable and contributes towards preserving quality of life of eligible women.
Keywords: Oncotype DX test; adjuvant chemotherapy; breast cancer; multigene assays; recurrence score results.
Similar articles
- Gene expression profiling for guiding adjuvant chemotherapy decisions in women with early breast cancer: an evidence-based and economic analysis.Ont Health Technol Assess Ser. 2010;10(23):1-57. Epub 2010 Dec 1.PMID: 23074401 Free PMC article.
- Tumour profiling tests to guide adjuvant chemotherapy decisions in early breast cancer: a systematic review and economic analysis.Health Technol Assess. 2019 Jun;23(30):1-328. doi: 10.3310/hta23300.PMID: 31264581 Free PMC article.
- Prospective observational study on the impact of the 21-gene assay on treatment decisions and resources optimization in breast cancer patients in Lombardy: The BONDX study.Breast. 2020 Aug;52:1-7. doi: 10.1016/j.breast.2020.04.003. Epub 2020 Apr 15.PMID: 32325372 Free PMC article.
- Ki67 and lymphocytes in the pretherapeutic core biopsy of primary invasive breast cancer: positive markers of therapy response prediction and superior survival.Horm Mol Biol Clin Investig. 2017 Sep 22;32(2):/j/hmbci.2017.32.issue-2/hmbci-2017-0022/hmbci-2017-0022.xml. doi: 10.1515/hmbci-2017-0022.PMID: 28937963 Review.
- Multigene assays in early breast cancer: Insights from recent phase 3 studies.Eur J Surg Oncol. 2020 Apr;46(4 Pt A):656-666. doi: 10.1016/j.ejso.2019.10.019. Epub 2019 Oct 15.PMID: 31706719 Review.
No hay comentarios:
Publicar un comentario